121 related articles for article (PubMed ID: 38844797)
1. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
Chen YB; Mohty M; Zeiser R; Teshima T; Jamy O; Maertens J; Purtill D; Chen J; Cao H; Rossiter G; Jansson J; Fløisand Y
Nat Med; 2024 Jun; ():. PubMed ID: 38844797
[TBL] [Abstract][Full Text] [Related]
2. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Chen YB; Shah NN; Renteria AS; Cutler C; Jansson J; Akbari M; Chen C; Quadri S; Parfionovas A; Devine SM
Blood Adv; 2019 Dec; 3(23):4136-4146. PubMed ID: 31821456
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M
Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
[TBL] [Abstract][Full Text] [Related]
4. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
6. Gut Immunomodulation with Vedolizumab prior to Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Inflammatory Bowel Disease.
Chopra Y; Acevedo K; Muise A; Frost K; Schechter T; Krueger J; Ali M; Chiang KY; Kim VH; Grunebaum E; Wall D
Transplant Cell Ther; 2024 May; 30(5):546.e1-546.e7. PubMed ID: 38458476
[TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation.
Yazdandoust E; Hajifathali A; Roshandel E; Zarif MN; Pourfathollah AA; Parkhideh S; Mehdizadeh M; Amini-Kafiabad S
Transpl Immunol; 2023 Jun; 78():101836. PubMed ID: 37037266
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab for pediatric patients with gastrointestinal acute graft-versus-host-disease.
Aldouby Bier G; Zaidman I; Dinur Schejter Y; NaserEddin A; Stepensky P; Even-Or E
Pediatr Blood Cancer; 2023 Jan; 70(1):e30061. PubMed ID: 36326084
[TBL] [Abstract][Full Text] [Related]
10. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
Chen X; Wei JL; Huang Y; He Y; Yang DL; Jiang EL; Ma QL; Zhou LK; Lin XT; Shen YY; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):610-4. PubMed ID: 23134851
[TBL] [Abstract][Full Text] [Related]
11. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
12. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3
Lum SH; James B; Ottaviano G; Ewins AM; Patrick K; Ali S; Carpenter B; Silva J; Tewari S; Furness C; Thomas A; Shenton G; Bonney D; Moppett J; Hambleton S; Gennery AR; Amrolia P; Gibson B; Hough R; Rao K; Slatter M; Wynn R
Transplant Cell Ther; 2024 Mar; 30(3):314.e1-314.e12. PubMed ID: 38103787
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis.
Li AC; Dong C; Tay ST; Ananthakrishnan A; Ma KS
Front Immunol; 2022; 13():1025350. PubMed ID: 36439135
[TBL] [Abstract][Full Text] [Related]
14. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
Yu J; Parasuraman S; Shah A; Weisdorf D
Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
[TBL] [Abstract][Full Text] [Related]
15. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
[TBL] [Abstract][Full Text] [Related]
16. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
[TBL] [Abstract][Full Text] [Related]
17. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
18. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Study of Intestinal Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Children].
Wang Z; Tao F; Tang W; Nie YM; Yang L; Chen Z; Teng JX; Lu WJ; Qi SS; Xiong H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):600-606. PubMed ID: 35396003
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
